Systematic Overview of Warfarin and Its Drug and Food Interactions
2005· review· en· Archives of Internal Medicine· Pharmacology, Toxicology and Pharmaceutics
aff
1,163
citations
Works
Every work in the frame. Each row carries the routes that admitted it, because a frame that forgets how it found something cannot be audited.
Route
Field
Type
Language
Year range
to
Screen consensus
Sort
Flags
Screening evidence
Direct labels are sparse and unvalidated. Missing labels are unknown.
1 filter active
1,519 workspage 1 of 61
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
2015· article· en· Clinical Pharmacology & Therapeutics· Pharmacology, Toxicology and Pharmaceutics
aff
975
citations
St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor
2000· article· en· Proceedings of the National Academy of Sciences· Pharmacology, Toxicology and Pharmaceutics
aboutno aff
938
citations
Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition
2000· review· en· Clinical Pharmacokinetics· Pharmacology, Toxicology and Pharmaceutics
affno abstract
907
citations
THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVE
2003· article· en· Drug Metabolism and Disposition· Pharmacology, Toxicology and Pharmaceutics
affno abstract
784
citations
Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update
2016· article· en· Clinical Pharmacology & Therapeutics· Pharmacology, Toxicology and Pharmaceutics
afffund
678
citations
Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother
2006· article· en· The Lancet· Pharmacology, Toxicology and Pharmaceutics
affno abstract
678
citations
UDP-glucuronosyltransferases and clinical drug-drug interactions
2005· review· en· Pharmacology & Therapeutics· Pharmacology, Toxicology and Pharmaceutics
affno abstract
546
citations
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
2021· article· en· British Journal of Pharmacology· Pharmacology, Toxicology and Pharmaceutics
aff
488
citations
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
2008· article· en· Blood· Pharmacology, Toxicology and Pharmaceutics
aff
486
citations
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants
2013· article· en· Clinical Pharmacology & Therapeutics· Pharmacology, Toxicology and Pharmaceutics
afffund
453
citations
Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process
2014· article· en· Current Drug Metabolism· Pharmacology, Toxicology and Pharmaceutics
afffund
436
citations
Pharmacogenomics of human UDP-glucuronosyltransferase enzymes
2003· review· en· The Pharmacogenomics Journal· Pharmacology, Toxicology and Pharmaceutics
affno abstract
423
citations
CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants:
a first step towards subpopulation‐specific dosages
2001· article· en· Acta Psychiatrica Scandinavica· Pharmacology, Toxicology and Pharmaceutics
aboutno aff
423
citations
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants
2023· article· en· Clinical Pharmacology & Therapeutics· Pharmacology, Toxicology and Pharmaceutics
aff
403
citations
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy
2021· article· en· Clinical Pharmacology & Therapeutics· Pharmacology, Toxicology and Pharmaceutics
aff
399
citations
Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method.
2000· review· en· Pharmacogenetics· Pharmacology, Toxicology and Pharmaceutics
aff
397
citations
An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures
2000· article· en· Phytomedicine· Pharmacology, Toxicology and Pharmaceutics
affno abstract
350
citations
Structural basis for pregnenolone biosynthesis by the mitochondrial monooxygenase system
2011· article· en· Proceedings of the National Academy of Sciences· Pharmacology, Toxicology and Pharmaceutics
afffund
342
citations
Warfarin: almost 60 years old and still causing problems
2006· article· en· British Journal of Clinical Pharmacology· Pharmacology, Toxicology and Pharmaceutics
aboutno aff
332
citations
Relative Enzymatic Activity, Protein Stability, and Tissue Distribution of Human Steroid-Metabolizing UGT2B Subfamily Members**This work was supported by the Medical Research Council of Canada, the Fonds de la Recherche en Sante du Quebec, and Endorecherche.
2001· article· en· Endocrinology· Pharmacology, Toxicology and Pharmaceutics
affabout
330
citations
2.1 Å Crystal Structure of Human PXR in Complex with the St. John's Wort Compound Hyperforin,
2003· article· en· Biochemistry· Pharmacology, Toxicology and Pharmaceutics
aboutno aff
317
citations
When good drugs go bad
2007· article· en· Nature· Pharmacology, Toxicology and Pharmaceutics
affno abstract
282
citations
Structural Basis of Human CYP51 Inhibition by Antifungal Azoles
2010· article· en· Journal of Molecular Biology· Pharmacology, Toxicology and Pharmaceutics
afffundno abstract
266
citations
MS E with mass defect filtering for in vitro and in vivo metabolite identification
2007· article· en· Rapid Communications in Mass Spectrometry· Pharmacology, Toxicology and Pharmaceutics
aff
254
citations